Background: C34T variant of adenosine monophosphate deaminase 1 (AMPD1) gene has been associated with a prolonged survival in heart failure and coronary artery disease, hypothetically linked to an enhanced production of adenosine. Design: Since adenosine administration is a promising approach for the prevention of the ischemia-reperfusion in myocardial revascularization, the aim of this study was to investigate whether the AMPD1 () allele is associated with a favorable prognosis after coronary revascularization. In addition, we assessed the association between AMPD1 polymorphism and plasma adenosine levels. Methods: We investigated a total of 161 patients receiving coronary revascularization (70 percutaneous transluminal coronary angioplasty and 91 coronary artery bypass graft). They were investigated for a composite endpoint including recurrent angina, non-fatal MI, target vessel revascularization, heart failure and cardiac death. Plasma adenosine was also measured by high-performance liquid chromatography methods on a subset of 25 patients. Results: During the follow-up period (7.0F0.3 months), the overall combined endpoint accounted for 17 events (10 cardiacrelated deaths, 6 revascularization procedures and 1 congestive heart failure). The composite endpoint was 9.8% for AMPD1 () allele carriers vs. 11.5% for non-carriers (log-rank statistic, p = n.s.). In the logistic analysis only low ( V 40%) ejection fraction was an independent predictor of adverse events ( p = 0.01, OR= 3.8, 95% CI 1.3-11.4). Plasma adenosine levels were similar for AMPD1 () allele patients (n = 7) as compared for AMPD1 (+) allele (n = 18) subjects (290.5F31.0 vs. 303.3F28.5 nM, p = n.s.). Conclusions: Our results indicate that AMPD1 () allele is not associated with a more favorable outcome after coronary revascularization. Alternative cardioprotective pathways of the AMPD1 gene--involving an enhanced chronic long-term production of adenosine--might be responsible for survival. D 2004 Elsevier Ireland Ltd. All rights reserved.

AMPD1 (C34T) polymorphism and clinical outcomes in patients undergoing myocardial revascularization

Biagini A;Picano E
2005

Abstract

Background: C34T variant of adenosine monophosphate deaminase 1 (AMPD1) gene has been associated with a prolonged survival in heart failure and coronary artery disease, hypothetically linked to an enhanced production of adenosine. Design: Since adenosine administration is a promising approach for the prevention of the ischemia-reperfusion in myocardial revascularization, the aim of this study was to investigate whether the AMPD1 () allele is associated with a favorable prognosis after coronary revascularization. In addition, we assessed the association between AMPD1 polymorphism and plasma adenosine levels. Methods: We investigated a total of 161 patients receiving coronary revascularization (70 percutaneous transluminal coronary angioplasty and 91 coronary artery bypass graft). They were investigated for a composite endpoint including recurrent angina, non-fatal MI, target vessel revascularization, heart failure and cardiac death. Plasma adenosine was also measured by high-performance liquid chromatography methods on a subset of 25 patients. Results: During the follow-up period (7.0F0.3 months), the overall combined endpoint accounted for 17 events (10 cardiacrelated deaths, 6 revascularization procedures and 1 congestive heart failure). The composite endpoint was 9.8% for AMPD1 () allele carriers vs. 11.5% for non-carriers (log-rank statistic, p = n.s.). In the logistic analysis only low ( V 40%) ejection fraction was an independent predictor of adverse events ( p = 0.01, OR= 3.8, 95% CI 1.3-11.4). Plasma adenosine levels were similar for AMPD1 () allele patients (n = 7) as compared for AMPD1 (+) allele (n = 18) subjects (290.5F31.0 vs. 303.3F28.5 nM, p = n.s.). Conclusions: Our results indicate that AMPD1 () allele is not associated with a more favorable outcome after coronary revascularization. Alternative cardioprotective pathways of the AMPD1 gene--involving an enhanced chronic long-term production of adenosine--might be responsible for survival. D 2004 Elsevier Ireland Ltd. All rights reserved.
2005
Istituto di Fisiologia Clinica - IFC
coronary artery disease
AMPD1 gene
PTCA
CABG
Clinical outcomes
File in questo prodotto:
File Dimensione Formato  
prod_23726-doc_20464.pdf

non disponibili

Descrizione: Articolo pubblicato
Dimensione 122.69 kB
Formato Adobe PDF
122.69 kB Adobe PDF   Visualizza/Apri   Richiedi una copia

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/20.500.14243/45866
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus ND
  • ???jsp.display-item.citation.isi??? 9
social impact